The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.

UPCOMING EDUCATIONAL OPPORTUNITIES

2024 Annual Meeting

Lunchtime webinar Series

October 24, 2024 at 12:15pm

Building Resiliency to Compassion Fatigue

RESEARCH, PROJECT & PROGRAM FUNDING


Fall Submission Deadline - September 15th


Fall Submission Deadline

October 15th


Up to $4,000 to fund your educational program.

Rolling Application Deadline

NNECOS PATIENT PHILANTHROPY


Rolling Application Deadline

Up to $3,000 per grant


Rolling Application Deadline

Up to 125, $25 grocery/cards 


OTHER NEWS & INFORMATION

New! Patient Advisor!

NNECOS is delighted to announce the appointment of Tawnya McDonald as the inaugural NNECOS Patient/Caregiver Advisor. Tawnya will serve as a partner to the NNECOS Board of Directors, sharing feedback, generating ideas, and offering insight from a patient perspective, providing invaluable opinoins based on personal experience with aspects of care. 

NNECOS Classifieds

Visit the NNECOS Member Classifieds for more information about job listings from the following centers:

  • UVM Cancer Center, Larner College of Medicine 
  • Northern Light Eastern Maine Medical Center Cancer Care

  • Dartmouth Cancer Center

  • UVM Cancer Center

  • Beth Israel Lahey Health Exeter

Drug Shortages Sign On Letter

Looking Back!

Enjoy this wonderful interview with 3 of NNECOS' founding members!



SOCIAL MEDIA

 

Group Practice Members

Because your entire team benefits
from being a part of NNECOS!

Participate on a NNECOS Task Force


FDA Approvals & uPDATES

Latest FDA Approval

  • October 10 - FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
  • October 3 - FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer
  • September 27 - FDA approves selpercatinib for medullary thyroid cancer with a RET mutation
  • September 25 - FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
  • September 20 - FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
  • September 19 - FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
  • September 17 - FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
  • September 17 - FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack for early high-risk breast cancer
  • September 12 - FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
  • August 19 - FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer
  • August 15 - FDA approves neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer
  • August 14 -FDA approves axatilimab-csfr for chronic graft-versus-host disease 
  • August 6 - FDA approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
  • August 2 - FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma
  • August 1 - FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy
  • July 30 - FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma

Package/Label Updates


    Code Updates

    • Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
    J1323- Injection, elranatamab-bcmm, 1 mg

    Other Updates


    Thank You Corporate Members!


    THANK YOU DIAMOND & PLATINUM CORPORATE MEMBERS


           
       


     

     


         
             
             



    View the complete list of corporate members.




    Northern New England Clinical Oncology Society
    P.O. Box 643
    Sandown, NH 03873-0643
    Telephone (603) 887-1948
    info@nnecos.org

    This website brought to you by:


    Powered by Wild Apricot Membership Software